Literature DB >> 6682656

cis-Pt(NH3)2Cl2 and trans-Pt(NH3)2Cl2 inhibit DNA synthesis in cultured L1210 leukemia cells.

B Salles, J L Butour, C Lesca, J P Macquet.   

Abstract

A comparison of the inhibition of DNA synthesis by the two geometrical bidentate isomers cis- and trans-Pt(NH3)2Cl2 and by the monodentate [Pt(dien)Cl]Cl in a model used for screening potential antitumor compounds, the L1210 leukemia cells, is presented. The efficacy of penetration after a 2 hours Pt treatment is in the order trans (8) greater than cis (1) approximately dien (0.7). DNA replication is reduced to 50% of the control when 1.8 X 10(-4), 2.4 X 10(-4) and 80 X 10(-4) Pt atoms were bound per nucleotide for cis, trans and dien derivatives, respectively. If we admit that DNA is the pharmacological target of Pt antitumor compounds, these results suggest that a quantitative inhibition of DNA synthesis is certainly not correlated with antitumor activity.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6682656     DOI: 10.1016/0006-291x(83)91500-0

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Treatment of DNA with ammonium bicarbonate or thiourea can lead to underestimation of platinum-DNA monoadducts.

Authors:  G R Gibbons; J D Page; S G Chaney
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Repair synthesis by human cell extracts in cisplatin-damaged DNA is preferentially determined by minor adducts.

Authors:  P Calsou; P Frit; B Salles
Journal:  Nucleic Acids Res       Date:  1992-12-11       Impact factor: 16.971

3.  cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines.

Authors:  M G Ormerod; C O'Neill; D Robertson; L R Kelland; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1996       Impact factor: 3.333

4.  The anti-tumour agent, cisplatin, and its clinically ineffective isomer, transplatin, produce unique gene expression profiles in human cells.

Authors:  Anne M Galea; Vincent Murray
Journal:  Cancer Inform       Date:  2008-06-10

5.  Cisplatin and ultra-violet-C synergistically down-regulate receptor tyrosine kinases in human colorectal cancer cells.

Authors:  Junji Kawaguchi; Seiji Adachi; Ichiro Yasuda; Takahiro Yamauchi; Masanori Nakashima; Tomohiko Ohno; Masahito Shimizu; Takashi Yoshioka; Masahiko Itani; Osamu Kozawa; Hisataka Moriwaki
Journal:  Mol Cancer       Date:  2012-07-12       Impact factor: 27.401

6.  The role of apoptosis in cell killing by cisplatin: a flow cytometric study.

Authors:  M G Ormerod; R M Orr; J H Peacock
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

Review 7.  Cisplatin-Induced Nephrotoxicity; Protective Supplements and Gender Differences

Authors:  Mehdi Nematbakhsh; Zahra Pezeshki; Fatemeh Eshraghi Jazi; Bahar Mazaheri; Maryam Moeini; Tahereh Safari; Fariba Azarkish; Fatemeh Moslemi; Maryam Maleki; Alireza Rezaei; Shadan Saberi; Aghdas Dehghani; Maryam Malek; Azam Mansouri; Marzieh Ghasemi; Farzaneh Zeinali; Zohreh Zamani; Mitra Navidi; Sima Jilanchi; Soheyla Shirdavani; Farzaneh Ashrafi
Journal:  Asian Pac J Cancer Prev       Date:  2017-02-01

8.  Glutathione restores normal cell activation and cell cycle progression in cis-platinum treated human lymphocytes.

Authors:  M Kubbies; B Goller; B Schetters; I Bartosek; W Albert
Journal:  Br J Cancer       Date:  1991-11       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.